E-Mail
Cancers that are resistant to radiotherapy could be rendered susceptible through treatment with immunotherapy, a new study suggests.
Researchers believe that manipulating bowel cancers based on their immune landscape could unlock new ways to treat resistant tumours.
Cancers can evolve resistance to radiotherapy just as they do with drugs.
The new study found that profiling the immune landscape of cancers before therapy could identify patients who are likely to respond to radiotherapy off the bat, and others who might benefit from priming of their tumour with immunotherapy.
Scientists at The Institute of Cancer Research, London, in collaboration with the University of Leeds and The Francis Crick Institute, studied inflammation in bowel tumour samples taken before and after radiotherapy from 53 patients. They aimed to understand how tumour immune activity before and after radiotherapy differs between patients who respond well and those who respond poorly to treatment.
Established therapy could bring new hope to patients with triple negative breast cancer
imt.ie - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from imt.ie Daily Mail and Mail on Sunday newspapers.
Unexpected beauty of cancer research revealed in competition shortlist
newscientist.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newscientist.com Daily Mail and Mail on Sunday newspapers.
Cancer Research UK teams up with Teon on new cancer drug
2nd March 2021
The focus of the agreement is Teon’s potentially first-in-class small molecule adenosine A2B receptor antagonist, TT-702.
Under the terms of the agreement, CRUK will sponsor the first-in-human Phase I/II clinical development of TT-702. This will be led by a team at The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust.
The Centre for Drug Development, Teon and a team of clinical investigators led by professor Johann de Bono are currently preparing to launch the early clinical trial in the second half of 2021.